Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen
Sponsor: ECOG-ACRIN Cancer Research Group
A PHASE2 clinical study on Breast Cancer and Stage IV Breast Cancer, this trial is completed. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 11 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Jul 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .